INS and type 2 diabetes mellitus: Since the discovery of medium- and long-chain FFAs as the endogenous ligand of GPR40 and the mechanism of FFA-induced insulin secretion in β-cells via GPR40 activation (Itoh et al., 2003), GPR40 agonist had been actively pursued as a new therapy for T2D.